{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:13:47Z","timestamp":1791357227717,"version":"4.3.1"},"update-to":[{"DOI":"10.1002\/14651858.cd009555","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T00:00:00Z","timestamp":1497398400000}}],"reference-count":103,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009555.pub2","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T09:00:00Z","timestamp":1497430800000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Clozapine dose for schizophrenia"],"prefix":"10.1002","volume":"2017","author":[{"given":"Selvizhi","family":"Subramanian","sequence":"first","affiliation":[{"name":"Morecambe Community Mental Health Team; Department of Psychiatry; Victoria House Thornton RD Morecambe UK LA4 5NN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit A","family":"V\u00f6llm","sequence":"additional","affiliation":[{"name":"University of Nottingham Innovation Park; Division of Psychiatry & Applied Psychology; Institute of Mental Health Triumph Road Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Huband","sequence":"additional","affiliation":[{"name":"University of Nottingham Innovation Park; Division of Psychiatry & Applied Psychology; Institute of Mental Health Triumph Road Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,14]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD009555.pub2-BIB0001|cit1","first-page":"104","article-title":"A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia","volume":"31","author":"Chen","year":"1998","journal-title":"Chinese Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0002|cit2","unstructured":"Chen YH Cao Q Chen WQ The effect of clozapine for patients with schizophrenia: a clinical trial Modern Diagnosis and Treatment [\u73b0\u4ee3\u8bca\u65ad\u4e0e\u6cbb\u7597] 2013 3460 1"},{"issue":"2","key":"10.1002\/14651858.CD009555.pub2-BIB0003|cit3","first-page":"98","article-title":"Effects of different doses clozapine on glucose metabolism in male schizophrenics","volume":"24","author":"Liu","year":"2005","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"issue":"2","key":"10.1002\/14651858.CD009555.pub2-BIB0004|cit4","first-page":"82","article-title":"Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia","volume":"38","author":"Liu","year":"2005","journal-title":"Chinese Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0005|cit5","unstructured":"Sheng XQ Hua K Yan H Luo LH Clozapine therapy in schizophrenia Chinese Journal of Nervous and Mental Disorders [\u4e2d\u56fd\u795e\u7ecf\u7cbe\u795e\u75be\u75c5\u6742\u5fd7] 1990 90 2"},{"issue":"5","key":"10.1002\/14651858.CD009555.pub2-BIB0007|cit6","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1176\/ajp.158.5.834-a","article-title":"Correction","volume":"158","author":"Simpson","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD009555.pub2-BIB0006|cit7","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.156.11.1744","article-title":"Double blind study of clozapine dose response in chronic schizophrenia","volume":"156","author":"Simpson","year":"1999","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD009555.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/JCP.0b013e31802e513a","article-title":"Weight gain during a double-blind multidosage clozapine study","volume":"27","author":"Leon","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009555.pub2-BIB0009|cit9","first-page":"S94","article-title":"Evaluation by ancova of comparative bioavailability of two oral formulations of clozapine in steady state in schizophrenic volunteers under a different doses regime","volume":"87","author":"Borges","year":"2010","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"1-2","key":"10.1002\/14651858.CD009555.pub2-BIB0010|cit10","first-page":"207","article-title":"Does clozapine induce akathisia?","volume":"15","author":"Leon","year":"1995","journal-title":"Schizophrenia Research"},{"issue":"2-3","key":"10.1002\/14651858.CD009555.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.schres.2004.03.017","article-title":"Plasma clozapine concentration coefficients of variation in a long-term study","volume":"72","author":"Diaz","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1-2","key":"10.1002\/14651858.CD009555.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0920-9964(97)82783-1","article-title":"Tardive dyskinesia and extrapyramidal symptoms in treatment-resistant schizophrenics treated with clozapine","volume":"24","author":"Nair","year":"1997","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD009555.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1176\/ajp.158.5.834-a","article-title":"\"Double-blind study of clozapine dose response in chronic schizophrenia\": correction","volume":"158","author":"Simpson","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD009555.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.pnpbp.2005.04.031","article-title":"Does clozapine decrease smoking?","volume":"29","author":"Leon","year":"2005","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD009555.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/01.jcp.0000145340.53417.ca","article-title":"Haloperidol half-life after chronic dosing","volume":"24","author":"Leon","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD009555.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.jcp.0000085405.08426.73","article-title":"Serum antimuscarinic activity during clozapine treatment","volume":"23","author":"Leon","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD009555.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00406-004-0505-2","article-title":"Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment","volume":"254","author":"Leon","year":"2004","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"11","key":"10.1002\/14651858.CD009555.pub2-BIB0018|cit18","first-page":"655","article-title":"A study of beam changes after taking the different dosages of clozapine in patients with schizophrenic","volume":"15","author":"Guo","year":"2003","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"2","key":"10.1002\/14651858.CD009555.pub2-BIB0019|cit19","first-page":"138","article-title":"Controlled clinical trial of high versus low dose clozapine combined with sulpiride for schizophrenia","volume":"14","author":"Han","year":"2001","journal-title":"Shandong Archives of Psychiatry [\u5c71\u4e1c\u7cbe\u795e\u533b\u5b66]"},{"issue":"8","key":"10.1002\/14651858.CD009555.pub2-BIB0020|cit20","first-page":"56","article-title":"Effect of clozapine of different dosages on the cognitive function in patients with schizophrenia assessed by the changes of p300 potentials","volume":"9","author":"Liu","year":"2005","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"7","key":"10.1002\/14651858.CD009555.pub2-BIB0021|cit21","first-page":"687","article-title":"Clozapine - a potential antipsychotic agent without extrapyramidal manifestations","volume":"16","author":"Matz","year":"1974","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"8","key":"10.1002\/14651858.CD009555.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/0006-3223(94)00365-A","article-title":"Clozapine decreases smoking in patients with chronic schizophrenia","volume":"37","author":"McEvoy","year":"1995","journal-title":"Biological Psychiatry"},{"issue":"18","key":"10.1002\/14651858.CD009555.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0920-9964(96)85426-0","article-title":"A double blind, randomized trial comparing clozapine treatment within three distinct serum level ranges in patients with refractory chronic schizophrenia","volume":"22","author":"McEvoy","year":"1996","journal-title":"Schizophrenia Research"},{"issue":"2-3","key":"10.1002\/14651858.CD009555.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0920-9964(96)85717-3","article-title":"Clozapine-induced EEG changes as a function of clozapine serum levels","volume":"18","author":"McEvoy","year":"1996","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"119\u201327","DOI":"10.1016\/S1077-7229(98)80024-2","article-title":"Therapeutic effects of clozapine on tardive dyskinesia","volume":"5","author":"Nair","year":"1998","journal-title":"Cognitive and Behavioral Practice"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1376\u201383","DOI":"10.1016\/S0006-3223(98)00146-2","article-title":"Does akathisia influence psychopathology in psychotic patients treated with clozapine?","volume":"45","author":"Nair","year":"1999","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0920-9964(93)90555-W","article-title":"High and low dose of clozapine compared in a double-blind study","volume":"9","author":"Potkin","year":"1993","journal-title":"Schizophrenia Research"},{"issue":"Suppl B","key":"10.1002\/14651858.CD009555.pub2-BIB0028|cit28","first-page":"133","article-title":"Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia","volume":"55","author":"Potkin","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD009555.pub2-BIB0029|cit29","first-page":"335","article-title":"Research for clozapine in schizophrenia and the relationship between plasma clozapine concentration and clinical response","volume":"10","author":"Tang","year":"2000","journal-title":"Journal of Clinical Psychological Medicine [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"12","key":"10.1002\/14651858.CD009555.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1176\/ajp.153.12.1579","article-title":"Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges","volume":"153","author":"VanderZwaag","year":"1996","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD009555.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0006-3223(96)00298-3","article-title":"Clozapine-induced electroencephalogram changes as a function of clozapine serum levels","volume":"42","author":"Freudenreich","year":"1997","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD009555.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004714-199702000-00009","article-title":"The effects of clozapine on symptom clusters in treatment-refractory patients","volume":"17","author":"Abraham","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1192\/bjp.171.2.125","article-title":"Cost-effectiveness of clozapine. A UK clinic-based study","volume":"171","author":"Aitchison","year":"1997","journal-title":"British Journal of Psychiatry"},{"issue":"7066","key":"10.1002\/14651858.CD009555.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecing skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"18","key":"10.1002\/14651858.CD009555.pub2-BIB0035|cit35","first-page":"63\u2013101","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"8","author":"Arnt","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD009555.pub2-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006633.pub2","article-title":"Clozapine versus other atypical antipsychotics for schizophrenia","author":"Asenjo Lobos","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD009555.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0013-7006(05)82401-7","article-title":"Current issues on schizoaffective disorder","volume":"31","author":"Azorin","year":"2005","journal-title":"Encephale"},{"issue":"3","key":"10.1002\/14651858.CD009555.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11920-003-0041-1","article-title":"Outcome of schizophreniform disorder","volume":"5","author":"Benazzi","year":"2003","journal-title":"Current Psychiatry Reports"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1192\/bjp.157.3.351","article-title":"Langfeldt's schizophreniform psychoses fifty years later","volume":"157","author":"Bergem","year":"1990","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0041|cit41","first-page":"229","volume-title":"Royal Pharmaceutical Society","author":"British National Formulary","year":"Sep 2012"},{"issue":"4","key":"10.1002\/14651858.CD009555.pub2-BIB0042|cit42","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"4","key":"10.1002\/14651858.CD009555.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/schbul\/21.4.579","article-title":"Clozapine: efficacy and Safety","volume":"21","author":"Buchanan","year":"1995","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"681\u201390","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009555.pub2-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006324.pub2","article-title":"Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia","author":"Cipriani","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0046|cit46","unstructured":"The College of Mental Health Pharmacy www.cmhp.org.uk"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1192\/S0007125000296840","article-title":"General pharmacology of clozapine","volume":"17","author":"Coward","year":"1992","journal-title":"British Journal of Psychiatry Supplement"},{"issue":"11","key":"10.1002\/14651858.CD009555.pub2-BIB0048|cit48","first-page":"1057","article-title":"Schizoaffective disorder: clinical symptoms and present-day approach to treatment","volume":"38","author":"Danilevici\u016bte","year":"2002","journal-title":"Medicina (Kaunas)"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0049|cit49","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0050|cit50","unstructured":"Deeks JJ Higgins JPT Altman DG editor(s) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD009555.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"19","key":"10.1002\/14651858.CD009555.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0053|cit53","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR","author":"American Psychiatric Association","year":"2000"},{"issue":"7109","key":"10.1002\/14651858.CD009555.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD009555.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD009555.pub2-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000059.pub2","article-title":"Clozapine versus typical neuroleptic medication for schizophrenia","author":"Essali","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD009555.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009555.pub2-BIB0058|cit58","first-page":"S37\u201342","article-title":"Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs","volume":"12","author":"Gaebel","year":"1997","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0059|cit59","volume-title":"Oxford Shorter Textbook of Psychiatry","author":"Gelder","year":"2001"},{"issue":"5","key":"10.1002\/14651858.CD009555.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000284725","article-title":"Were Langfeldt's schizophreniform psychoses really affective?","volume":"24","author":"Guldberg","year":"1991","journal-title":"Psychopathology"},{"issue":"9","key":"10.1002\/14651858.CD009555.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"issue":"7414","key":"10.1002\/14651858.CD009555.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0063|cit63","unstructured":"Higgins JPT Green S editor(s) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0064|cit64","unstructured":"Higgins JPT Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD009555.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0066|cit66","volume-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","author":"World Health Organization","year":"2004"},{"issue":"9","key":"10.1002\/14651858.CD009555.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"789\u201396","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0068|cit68","first-page":"151\u20137","article-title":"Treatment programme and long term outcome in chronic schizophrenia","volume":"358","author":"Kane","year":"1990","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Kane JM A user guide to clozapine Acta Psychiatrica Scandinavica 2011 407 8","DOI":"10.1111\/j.1600-0447.2011.01711.x"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0070|cit70","volume-title":"Kaplan & Sadock's Comprehensive Text Book of Psychiatry","author":"Sadock","year":"2005"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/ajp.90.1.97","article-title":"The acute schizoaffective psychoses","volume":"90","author":"Kasanin","year":"1933","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0072|cit72","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1192\/apt.11.2.101","article-title":"Management of clozapine-resistant schizophrenia","volume":"11","author":"Kerwin","year":"2005","journal-title":"Advances in Psychiatric Treatment"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/ajp.152.2.179","article-title":"Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients","volume":"152","author":"Kronig","year":"1995","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD009555.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1037\/1040-3590.13.3.384","article-title":"New subscales for an anchored version of the Brief Psychiatric Rating Scale: construction, reliability, and validity in acute psychiatric admissions","volume":"13","author":"Lachar","year":"2001","journal-title":"Psychological Assessment"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD009555.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD009555.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiologic Reviews"},{"issue":"9426","key":"10.1002\/14651858.CD009555.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"2063\u201372","DOI":"10.1016\/S0140-6736(04)16458-1","article-title":"Schizophrenia","volume":"363","author":"Mueser","year":"2004","journal-title":"Lancet"},{"issue":"15","key":"10.1002\/14651858.CD009555.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD009555.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"223\u20139","DOI":"10.1185\/03007990152673864","article-title":"Focus on clozapine","volume":"17","author":"Naheed","year":"2001","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0084|cit84","unstructured":"National Institute for Health and Clinical Excellence (NICE) NICE clinical guideline 82: Schizophrenia core interventions in the treatment and management of schizophrenia in adults in primary and secondary care www.nice.org.uk\/guidance\/CG82"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0085|cit85","first-page":"1069","article-title":"TESS (treatment emergent symptoms scale)","volume":"22","author":"National Institute of Mental Health (NIMH)","year":"1985","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD009555.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"432\u201343","DOI":"10.1111\/j.1600-0447.1967.tb05780.x","article-title":"A prolonged follow-up of acute schizophrenic and schizophreniform psychoses","volume":"43","author":"Noreik","year":"1967","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"5","key":"10.1002\/14651858.CD009555.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0089|cit89","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0090|cit90","volume-title":"Oxford Handbook of Psychiatry","author":"Smyth","year":"2007"},{"issue":"5","key":"10.1002\/14651858.CD009555.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1176\/ajp.158.5.834-a","article-title":"Correction","volume":"158","author":"Simpson","year":"2001","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0092|cit92","volume-title":"Essential Psychopharmacology","author":"Stahl","year":"2006"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0093|cit93","unstructured":"Sterne JAC Egger M Moher D editor(s) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"3","key":"10.1002\/14651858.CD009555.pub2-BIB0094|cit94","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005579.pub2","article-title":"Pharmacological interventions for clozapine-induced hypersalivation","author":"Syed","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1192\/pb.19.12.753","article-title":"The use of clozapine plasma levels in optimising therapy","volume":"19","author":"Taylor","year":"1995","journal-title":"Psychiatric Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD009555.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"9690","key":"10.1002\/14651858.CD009555.pub2-BIB0097|cit97","first-page":"635\u201345","article-title":"Schizophrenia","volume":"374","author":"Os","year":"2009","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009555.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4088\/JCP.9096su1cc.03","article-title":"Developing an individualized treatment plan for patients with schizoaffective disorder: from pharmacotherapy to psychoeducation","volume":"71","author":"Vieta","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD009555.pub2-BIB0099|cit99","first-page":"77","article-title":"Should clozapine continue to be restricted to third-line status for schizophrenia?: A decision-analytic model","volume":"7","author":"Wang","year":"2004","journal-title":"Journal of Mental Health Policy and Economics"},{"issue":"1","key":"10.1002\/14651858.CD009555.pub2-BIB0100|cit100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008125.pub2","article-title":"Sulpiride augmentation for schizophrenia","author":"Wang","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009555.pub2-BIB0101|cit101","unstructured":"World Health Organisation Health topics, mental health, schizophrenia www.who.int\/mental_health\/management\/schizophrenia\/en\/"},{"issue":"1","key":"10.1002\/14651858.CD009555.pub2-BIB0102|cit102","first-page":"112","article-title":"Anchoring the BPRS: an aid to improved reliability","volume":"24","author":"Woerner","year":"1988","journal-title":"Psychopharmacology Bulletin"},{"issue":"7","key":"10.1002\/14651858.CD009555.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009555.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:47:51Z","timestamp":1768880871000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009555.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,6,14]]},"references-count":103,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009555.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,14]]}}}